I.R.C.C.S. Policlinico San Matteo, Pavia

Slides:

Advertisements

Similar presentations

Spanish Oncology GenitoUrinary Group

Advertisements

ASCO G.U Lawrence H. Einhorn.

Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:

Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.

Michele Milella Oncologia Medica A Istituto Nazionale Tumori Regina Elena Roma.

Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.

Advanced NSCLC Objective response rate -Well defined & widely accepted -Does not correlate well with OS -May be more useful if SD included -Higher RR correlates.

Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI

Dr. Camillo Porta S.C. di Oncologia Medica, I.R.C.C.S. Fondazione Policlinico San Matteo, Pavia.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Renal Cancer Immunotherapy Walter Stadler. 2 Renal cancer natural history.

Biological and Molecular Targeted Therapy for HHC

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Clinical case HIGHLIGTHS IN ADVANCED RENAL CELL CARCINOMA MANAGEMENT Roma, 24 febbraio 2012 Cristina Masini Azienda Ospedaliero Universitaria Policlinico.

ERCC 1 isoform expression and DNA repair in NSCLC

Neo-adjuvant therapies for RCC Dr. Camillo Porta S.C. di Oncologia Medica I.R.C.C.S. Policlinico San Matteo, Pavia.

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

The genetic basis of myelodysplasia and its clinical relevance

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.

Experimental Design and Statistical Considerations in Translational Cancer Research (in 15 minutes) Elizabeth Garrett-Mayer, PhD Associate Professor of.

Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.

Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.

 Copy: few empirical studies compared to other treatments  Eysenck- reviewed 2 studies, incorporating waiting list controls, which showed that 66% of.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Adjuvant therapies for RCC Dr. Camillo Porta S.C. di Oncologia Medica I.R.C.C.S. Policlinico San Matteo, Pavia.

Challenges for the treatment of pancreatic and renal cell cancer Nick Thatcher Christie Hospital NHS Trust Manchester, UK.

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

Response evaluation in RCC Dr. Camillo Porta S.C. di Oncologia Medica I.R.C.C.S. Policlinico San Matteo, Pavia.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

ASCO 2009 BEVACIZUMAB IN METASTATIC RENAL CELL CARCINOMA: An Update of the CALGB and AVOREN Trials Reviewed by: Dr. Daniel.

COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib Telli ML, Witteles RM, Fisher GA, Srinivas S. Reviewed by:

Melanoma Nati Lerman MD Division of Hematology/Medical Oncology MD Anderson Cancer Center at Cooper September 2016.

Sérgio Barroso Department of Oncology

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Campos M et al. Proc EHA 2013;Abstract B2009.

Campos M et al. Proc EHA 2013;Abstract B2009.

Università Politecnica delle Marche AOU Ospedali Riuniti “Umberto I – GM Lancisi – G Salesi” Ancona - Italy The role of tumour Vascular Endothelial Growth.

Pazopanib: the role in the treatment of mRCC

Tx response evaluation in RCC I.R.C.C.S. Policlinico San Matteo, Pavia

Mateos MV et al. Proc ASH 2013;Abstract 403.

Jabbour E et al. Proc ASH 2015;Abstract 83.

Second-line Therapy and Beyond for Advanced Renal Cell Carcinoma

Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.

Metastatic Renal Cell Carcinoma

Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center

Barrios C et al. SABCS 2009;Abstract 46.

Treating mRCC After Initial Antiangiogenic Therapy:

بسمه تعالی کارگاه ارزشیابی پیشرفت تحصیلی

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Advancing the Treatment of IBD With Biologics

Figure 3 Summary of overall survival by Kaplan–Meier

Domenica 03 giugno Highlight a cura di Filippo de Marinis

Valencia, España SESION CONTROVERSIAS ¿Es necesario modificar el desarrollo clínico de los nuevos fármacos? COMENTARIOS Y DISCUSION Andres.

Great Debates-CML Omacetaxine succinate

Supplemental Figure 1A Pt Pt Pre-treatment

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Supplementary Figure 2 Shiota et al.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Ali Shamseddine,MD,FRCP

Björn Bornkamp, Georgina Bermann

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

I.R.C.C.S. Policlinico San Matteo, Pavia Platinum series: best papers on RCC in 2013 Dr. Camillo Porta S.C. di Oncologia Medica I.R.C.C.S. Policlinico San Matteo, Pavia

What I wanted to tell you about … but I can’t The final publication of the COMPARZ trial (already accepted by the NEJM) The final publication of the PISCES trial (revision just submitted to the JCO)

Content of the presentation Therapeutics final results of the AXIS trial TKI-mTORI-TKI or TKI-TKI-mTORI? selection criteria for immunotherapy and its efficacy post-TKIs Prognostic criteria validation of the Heng’s score prognostic factors for survival in Sunitinib-treated patients Translational research Sunitinib Tx and tumor growth

The AXIS trial

AXIS trial final OS results

AXIS trial final OS results: overall patient population

AXIS trial final OS results: other analyses Post Sunitinib Post cytokines

Patient Reported Outcomes AXIS trial results: Patient Reported Outcomes

AXIS trial results: no differences in PROs

Which sequence over 3 lines of treatment?

Few patients receive 3 drugs, but the winner is …

high-dose IL-2 immunotherapy Targeted agents after high-dose IL-2 immunotherapy

High-dose IL-2 immunotherapy: which patients?

High-dose IL-2 immunotherapy after targeted agents Does these results really mean something?

Validation of the Heng’s criteria

Different models compared

And the winner is …

Prognostic factors for survival in Sunitinib treated pts

Prognostic factors for Sunitinib: nihil novo sub solem Motzer RJ et al. BJC 2013

Sunitinib and tumor growth

Is a strong angiogenesis inhibition linked to a rapid tumor progression?

Sunitinib does not alter tumor biology in vivo

Thank You for Your kind attention!!! c.porta@smatteo.pv.it